- Trials with a EudraCT protocol (2,294)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2,294 result(s) found for: Disease Specific Survival.
Displaying page 1 of 115.
EudraCT Number: 2018-000515-24 | Sponsor Protocol Number: RG_17-247 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma | |||||||||||||
Medical condition: Rhabdomyosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) NO (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) DK (Ongoing) SI (Ongoing) GR (Ongoing) CZ (Ongoing) IT (Ongoing) SE (Ongoing) AT (Ongoing) BE (Ongoing) FI (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000091-41 | Sponsor Protocol Number: UCL/11/0404 | Start Date*: 2012-10-22 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine(HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG) | |||||||||||||
Medical condition: High Grade glioma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001186-85 | Sponsor Protocol Number: HIVEC-HR | Start Date*: 2016-06-09 |
Sponsor Name:Dr. Felipe Villacampa | ||
Full Title: HIVEC HR: USE OF CHEMOHYPERTHERMIA WITH INTRAVESICAL MITOMYCIN (HIVEC) FOR THE TREATMENT OF PATIENTS WITH NMIBC AND HIGH RISK (HR) | ||
Medical condition: Non Muscle Invasive Bladder Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002447-16 | Sponsor Protocol Number: 111482 | Start Date*: 2008-11-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma | |||||||||||||
Medical condition: Patients with histologically proven stage IIIB or IIIC cutaneous melanoma with macroscopic lymph node involvement suitable for surgical resection. Macroscopic lymph node involvement is defined as c... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004200-21 | Sponsor Protocol Number: SUGBG-KIR-2018-001 | Start Date*: 2018-10-05 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
Full Title: A phase Ib/II randomized double-blind placebo controlled trial evaluating the effect of nivolumab for patients with in-transit melanoma metastases treated with isolated limb perfusion | |||||||||||||
Medical condition: Malignant melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004952-13 | Sponsor Protocol Number: DART | Start Date*: 2020-12-14 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) | |||||||||||||
Medical condition: - Prostate cancer patients with a biochemical recurrence following primary therapy - Hormone-sensitive - Up to 5 metastases on PSMA PET-CT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002429-12 | Sponsor Protocol Number: UC_0160/1613 | Start Date*: 2018-01-31 |
Sponsor Name:UNICANCER | ||
Full Title: PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY | ||
Medical condition: Metastatic castrate-resistant prostate cancer requiring initiation of chemotherapy | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005817-61 | Sponsor Protocol Number: iVAC-CLL01 | Start Date*: 2016-07-28 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: iVAC-CLL01: Patient-individualized peptide vaccination after first line therapy of CLL | |||||||||||||
Medical condition: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) after first line therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003809-22 | Sponsor Protocol Number: MDS | Start Date*: 2022-09-09 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syn... | ||
Medical condition: Myelodysplastic syndrome (MDS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004353-32 | Sponsor Protocol Number: GECP16/06 | Start Date*: 2017-09-01 |
Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP) | ||
Full Title: Survival, quality of life and self-reported outcomes of elderly patients with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (MK-3475) in the first line setting | ||
Medical condition: First line treatment in PD-L1 positive advanced non-small cell lung cancer patients | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2011-003078-10 | Sponsor Protocol Number: SPCG 16 | Start Date*: 2011-11-02 | |||||||||||
Sponsor Name:SPCG | |||||||||||||
Full Title: SPCG 16 Sensi-cab Randomized phase III trial comparing cabazitaxel in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer | |||||||||||||
Medical condition: Patients diagnosed with metastatic or high risk(PSA>100 or N1) prostate cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001077-87 | Sponsor Protocol Number: IJB-RT-HNC-001 | Start Date*: 2019-08-08 | |||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||
Full Title: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients t... | |||||||||||||
Medical condition: advanced head and neck cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004373-40 | Sponsor Protocol Number: AveNEC | Start Date*: 2017-08-21 |
Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz | ||
Full Title: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) pr... | ||
Medical condition: advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000259-28 | Sponsor Protocol Number: 54179060LYM3003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma. | |||||||||||||
Medical condition: Mature B-Cell Neoplasm | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) Outside EU/EEA SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000899-15 | Sponsor Protocol Number: EORTC-1531-ROG | Start Date*: 2019-12-03 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study | |||||||||||||
Medical condition: Intermediate and Limited High Risk Localized Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001022-22 | Sponsor Protocol Number: COV-2-STs | Start Date*: 2021-05-14 |
Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου" | ||
Full Title: Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients | ||
Medical condition: COVID-19 high-risk patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000269-30 | Sponsor Protocol Number: MO29518 | Start Date*: 2015-08-26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressed following at least one line of prior systemic anticancer therapy, or ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) IE (Completed) AT (Completed) ES (Completed) FI (Completed) GB (Completed) DK (Completed) PL (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002400-40 | Sponsor Protocol Number: FFCD1709 | Start Date*: 2020-07-27 |
Sponsor Name:Fédération Francophone de Cancérologie Digestive | ||
Full Title: A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) ... | ||
Medical condition: MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003626-40 | Sponsor Protocol Number: CA209-274 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma | |||||||||||||
Medical condition: Subjects with High Risk Invasive Urothelial Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) SE (Ongoing) PL (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) RO (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005225-37 | Sponsor Protocol Number: 16-12301 | Start Date*: 2019-12-10 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: The ASTEROID trial - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patien... | ||
Medical condition: Stage I Non-small cell lung cancer (NSCLC) that has been treated with Stereotactic Body Radiotherapy (SBRT). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.